Esperion Therapeutics, Daiichi Sankyo Europe Ink $125 Mln Amendment To Their Collaboration

RTTNews | 559 days ago
Esperion Therapeutics, Daiichi Sankyo Europe Ink $125 Mln Amendment To Their Collaboration

(RTTNews) - Esperion Therapeutics, Inc. (ESPR) and Daiichi Sankyo Europe GmbH or DSE, the European arm of Japanese pharmaceutical company Daiichi Sankyo Co., Ltd. (DSKYF.PK), announced Wednesday a $125 million amendment to their collaboration, which includes an amicable resolution to their commercial dispute and certain other adjustments to enhance the long-term value of their products.

DSE has agreed to pay Esperion $100 million in mid-January ahead of an anticipated Type II(a) variation approval by the European Medicines Agency (EMA) for NILEMDO (bempedoic acid) Tablet and NUSTENDI (bempedoic acid and ezetimibe) Tablet.

DSE will make an additional $25 million payment to Esperion in the calendar quarter immediately following EMA's decision on the pending application.

The legal action pending in the United States District Court for the Southern District of New York will be dismissed.

Since 2019, Esperion and DSE have worked together to bring bempedoic acid to the eligible patient population and unlock its potential for cardiovascular risk reduction. The partnership continues to grow, with DSE recently gaining approvals for bempedoic acid in the Netherlands, Slovakia, and Spain.

read more
Merck, Daiichi Sankyo Say FDA Grants Priority Review In U.S. For Patritumab Deruxtecan

Merck, Daiichi Sankyo Say FDA Grants Priority Review In U.S. For Patritumab Deruxtecan

Merck & Co. Inc. (MRK) and Japan's Daiichi Sankyo Co. Ltd. (DSKYF.PK) announced Friday that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the Biologics License Application (BLA) for patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies.
RTTNews | 571 days ago
Asian Shares Rise After Key China Data

Asian Shares Rise After Key China Data

Asian stocks rose broadly on Tuesday as traders brushed off U.S. President Donald Trump's tariff threats and reacted positively to Chinese GDP data for the first half of 2025.
RTTNews | 1h 17min ago
Yen Slides Against Majors

Yen Slides Against Majors

The Japanese yen weakened against other major currencies in the European session on Tuesday.
RTTNews | 1h 19min ago
China GDP Growth Tops Expectations

China GDP Growth Tops Expectations

China's economy registered a faster-than-expected growth in the second quarter with strong support from exports and industrial production despite the US trade tariff threats but weaker investment and persistent deflation continued to pose challenges. Gross domestic product expanded 5.2 percent on a yearly basis after rising 5.4 percent in the previous quarter.
RTTNews | 1h 58min ago
European Shares Seen Higher At Open

European Shares Seen Higher At Open

European stocks may open broadly higher on Tuesday despite lingering concerns about U.S. President Donald Trump's tariff plans and aggressive negotiation tactics.
RTTNews | 4h 8min ago
European Economic News Preview: German ZEW Economic Sentiment Due

European Economic News Preview: German ZEW Economic Sentiment Due

Economic confidence from Germany and industrial production from euro area are the top economic news due on Tuesday. At 3.00 am ET, Spain's statistical office INE publishes final inflation data for June. The flash estimate showed that consumer price inflation rose to 2.2 percent from 2.0 percent in May.
RTTNews | 4h 58min ago